|
1
|
Chen MM, Luu M, Sacks WL, Orloff L,
Wallner LP, Clair JM, Pitt SC, Ho AS and Zumsteg ZS: Trends in
incidence, metastasis, and mortality from thyroid cancer in the USA
from 1975 to 2019: A population-based study of age, period, and
cohort effects. Lancet Diabetes Endocrinol. 13:188–195. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
3
|
Boucai L, Zafereo M and Cabanillas ME:
Thyroid cancer: A review. JAMA. 331:425–435. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen F, Wu M, Ross JF, Miller D and Ratnam
M: Folate receptor type gamma is primarily a secretory protein due
to lack of an efficient signal for glycosylphosphatidylinositol
modification: Protein characterization and cell type specificity.
Biochemistry. 34:5660–5665. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang HC, Huo YN and Lee WS: Folic acid
prevents the progesterone-promoted proliferation and migration in
breast cancer cell lines. Eur J Nutr. 59:2333–2344. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moazzen S, Dolatkhah R, Tabrizi JS,
Shaarbafi J, Alizadeh BZ, de Bock GH and Dastgiri S: Folic acid
intake and folate status and colorectal cancer risk: A systematic
review and meta-analysis. Clin Nutr. 37:1926–1934. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sadeghi Jam Z, Tafvizi F, Khodarahmi P,
Jafari P and Baghbani-Arani F: Cisplatin-loaded UiO-66-NH2
functionalized with folic acid enhances apoptotic activity and
antiproliferative effects in MDA-MB-231 breast and A2780 ovarian
cancer cells: An in vitro study. Heliyon. 11:e426852025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crider KS, Yang TP, Berry RJ and Bailey
LB: Folate and DNA methylation: A review of molecular mechanisms
and the evidence for Folate's role. Adv Nutr. 3:21–38. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petersen LF, Brockton NT, Bakkar A, Liu S,
Wen J, Weljie AM and Bismar TA: Elevated physiological levels of
folic acid can increase in vitro growth and invasiveness of
prostate cancer cells. BJU Int. 109:788–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ullevig SL, Bacich DJ, Gutierrez JM,
Balarin A, Lobitz CA, O'Keefe DS and Liss MA: Feasibility of
dietary folic acid reduction intervention for men on active
surveillance for prostate cancer. Clin Nutr ESPEN. 44:270–275.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li JT, Yang H, Lei MZ, Zhu WP, Su Y, Li
KY, Zhu WY, Wang J, Zhang L, Qu J, et al: Dietary folate drives
methionine metabolism to promote cancer development by stabilizing
MAT IIA. Signal Transduct Target Ther. 7:1922022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qu Y, Zhang X, Qiao R, Di F, Song Y, Wang
J, Ji L, Zhang J, Gu W, Fang Y, et al: Blood FOLR3 methylation
dysregulations and heterogeneity in non-small lung cancer highlight
its strong associations with lung squamous carcinoma. Respir Res.
25:592024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Holm J and Hansen SI: Characterization of
soluble folate receptors (folate binding proteins) in humans.
Biological roles and clinical potentials in infection and
malignancy. Biochim Biophys Acta Proteins Proteom. 1868:1404662020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu MH, Luo JD, Wang WC, Chang TH, Hwang
WL, Lee KH, Liu SY, Yang JW, Chiou CT, Chang CH and Chiang WF: Risk
analysis of malignant potential of oral verrucous hyperplasia: A
follow-up study of 269 patients and copy number variation analysis.
Head Neck. 40:1046–1056. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hansen MF, Greibe E, Skovbjerg S, Rohde S,
Kristensen AC, Jensen TR, Stentoft C, Kjær KH, Kronborg CS and
Martensen PM: Folic acid mediates activation of the pro-oncogene
STAT3 via the Folate Receptor alpha. Cell Signal. 27:1356–1368.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma Q, Geng K, Xiao P and Zeng L:
Identification and prognostic value exploration of radiotherapy
sensitivity-Associated genes in Non-Small-cell lung cancer. Biomed
Res Int. 2021:59638682021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zee RY, Rose L, Chasman DI and Ridker PM:
Genetic variation of fifteen folate metabolic pathway associated
gene loci and the risk of incident head and neck carcinoma: The
Women's Genome Health Study. Clin Chim Acta. 418:33–36. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liao T, Zeng Y, Xu W, Shi X, Shen C, Du Y,
Zhang M, Zhang Y, Li L, Ding P, et al: A spatially resolved
transcriptome landscape during thyroid cancer progression. Cell Rep
Med. 6:1020432025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ritchie ME, Phipson B and Wu D, Ritchie
ME, Phipson B and Wu D: Limma powers differential expression
analyses for RNA-sequencing and microarray studies. Nucleic Acids
Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z,
Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A
universal enrichment tool for interpreting omics data. Innovation
(Camb). 2:1001412021.PubMed/NCBI
|
|
21
|
Li X, Zhang L, Liu C, He Y, Li X, Xu Y, Gu
C, Wang X, Wang S, Zhang J and Liu J: Construction of mitochondrial
quality regulation genes-related prognostic model based on
bulk-RNA-seq analysis in multiple myeloma. Biofactors.
51:e21352025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang X, Sun Y, Song J, Huang Y, Shi H,
Qian A, Cao Y, Zhou Y and Wang Q: Prognostic value of fatty acid
metabolism-related genes in colorectal cancer and their potential
implications for immunotherapy. Front Immunol. 14:13014522023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ning X, Li R, Zhang B, Wang Y, Zhou Z, Ji
Z, Lyu X and Chen Z: Immune score indicator for the survival of
melanoma patients based on tumor microenvironment. Int J Gen Med.
14:10397–10416. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao AY, Unterman A, Abu Hussein NS,
Sharma P, Nikola F, Flint J, Yan X, Adams TS, Justet A, Sumida TS,
et al: Single-cell analysis reveals novel immune perturbations in
fibrotic hypersensitivity pneumonitis. Am J Respir Crit Care Med.
210:1252–1266. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Li F, Xu L, Shi X, Xue H, Liu J, Bai
S, Wu Y, Yang Z, Xue F, et al: Single cell analyses reveal the PD-1
blockade response-related immune features in hepatocellular
carcinoma. Theranostics. 14:3526–3547. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin S, Guerrero-Juarez CF, Zhang L, Chang
I, Ramos R, Kuan CH, Myung P, Plikus MV and Nie Q: Inference and
analysis of cell-cell communication using CellChat. Nat Commun.
12:10882021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang A, Sun Z, Hong H, Yang Y, Chen J,
Gao Z and Gu J: Novel hypoxia- and lactate metabolism-related
molecular subtyping and prognostic signature for colorectal cancer.
J Transl Med. 22:5872024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 practice
guidance by the American association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Humphries MP, Maxwell P and Salto-Tellez
M: QuPath: The global impact of an open source digital pathology
system. Comput Struct Biotechnol J. 19:852–859. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wen Z, Luo D, Wang S, Rong R, Evers BM,
Jia L, Fang Y, Daoud EV, Yang S, Gu Z, et al: Deep Learning-Based
H-Score quantification of immunohistochemistry-stained images. Mod
Pathol. 37:1003982024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siena S, Raghav K, Masuishi T, Yamaguchi
K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M,
Kawakami H, et al: HER2-related biomarkers predict clinical
outcomes with trastuzumab deruxtecan treatment in patients with
HER2-expressing metastatic colorectal cancer: Biomarker analyses of
DESTINY-CRC01. Nat Commun. 15:102132024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li M, Hu M, Jiang L, Pei J and Zhu C:
Trends in cancer incidence and potential associated factors in
China. JAMA Netw Open. 7:e24403812024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miranda-Filho A, Lortet-Tieulent J, Bray
F, Cao B, Franceschi S, Vaccarella S and Dal Maso L: Thyroid cancer
incidence trends by histology in 25 countries: A population-based
study. Lancet Diabetes Endocrinol. 9:225–234. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tao Z, Ding Z, Guo B, Fan Y and Deng X:
Influence factors and survival outcomes of different invasion sites
in locally advanced thyroid cancer and new site-based risk
stratification system. Endocrine. 88:501–510. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu X, Deng Q, Gao X, He L, Hu D and Yang
L: A prognostic nomogram for distant metastasis in thyroid cancer
patients without lymph node metastasis. Front Endocrinol
(Lausanne). 16:15237852025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lv X and Yu X: Signatures and prognostic
values of related immune targets in tongue cancer. Front Surg.
9:9523892023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Davidson B, Abeler VM, Førsund M, Holth A,
Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM and Wang TL:
Gene expression signatures of primary and metastatic uterine
leiomyosarcoma. Hum Pathol. 45:691–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bin-Alee F, Arayataweegool A,
Buranapraditkun S, Mahattanasakul P, Tangjaturonrasme N, Hirankarn
N, Mutirangura A and Kitkumthorn N: Transcriptomic analysis of
peripheral blood mononuclear cells in head and neck squamous cell
carcinoma patients. Oral Dis. 27:1394–1402. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qiao R, Di F, Wang J, Wei Y, Xu T, Dai L,
Gu W, Han B and Yang R: Identification of FUT7 hypomethylation as
the blood biomarker in the prediction of early-stage lung cancer. J
Genet Genomics. 50:573–581. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li L, Wang R, He S, Shen X, Kong F, Li S,
Zhao H, Lian M and Fang J: The identification of induction
chemo-sensitivity genes of laryngeal squamous cell carcinoma and
their clinical utilization. Eur Arch Otorhinolaryngol.
275:2773–2781. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O'Byrne MR, Au KS, Morrison AC, Lin JI,
Fletcher JM, Ostermaier KK, Tyerman GH, Doebel S and Northrup H:
Association of folate receptor (FOLR1, FOLR2, FOLR3) and reduced
folate carrier (SLC19A1) genes with meningomyelocele. Birth Defects
Res A Clin Mol Teratol. 88:689–694. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grarup N, Sulem P, Sandholt CH,
Thorleifsson G, Ahluwalia TS, Steinthorsdottir V, Bjarnason H,
Gudbjartsson DF, Magnusson OT, Sparsø T, et al: Genetic
architecture of vitamin B12 and folate levels uncovered applying
deeply sequenced large datasets. PLoS Genet. 9:e10035302013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nawaz FZ and Kipreos ET: Emerging roles
for folate receptor FOLR1 in signaling and cancer. Trends
Endocrinol Metab. 33:159–174. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mai J, Wu L, Yang L, Sun T, Liu X, Yin R,
Jiang Y, Li J and Li Q: Therapeutic strategies targeting folate
receptor α for ovarian cancer. Front Immunol. 14:12545322023.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Matsunaga Y, Yamaoka T, Ohba M, Miura S,
Masuda H, Sangai T, Takimoto M, Nakamura S and Tsurutani J: Novel
Anti-FOLR1 Antibody-drug conjugate MORAb-202 in breast cancer and
non-Small cell lung cancer cells. Antibodies (Basel). 10:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen CI, Li WS, Chen HP, Liu KW, Tsai CJ,
Hung WJ and Yang CC: High expression of folate receptor alpha
(FOLR1) is associated with aggressive tumor behavior, poor response
to chemoradiotherapy, and worse survival in rectal cancer. Technol
Cancer Res Treat. 21:153303382211417952022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Varaganti P, Buddolla V, Lakshmi BA and
Kim YJ: Recent advances in using folate receptor 1 (FOLR1) for
cancer diagnosis and treatment, with an emphasis on cancers that
affect women. Life Sci. 326:121802M2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Medina JE, Annapragada AV, Lof P, Short S,
Bartolomucci AL, Mathios D, Koul S, Niknafs N, Noë M, Foda ZH, et
al: Early detection of ovarian cancer Using Cell-Free DNA
fragmentomes and protein biomarkers. Cancer Discov. 15:105–118.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Muinao T, Deka Boruah HP and Pal M:
Multi-biomarker panel signature as the key to diagnosis of ovarian
cancer. Heliyon. 5:e028262019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Heitz F, Lakis S, Harter P, Heikaus S,
Sehouli J, Talwar J, Menon R, Ataseven B, Bertrand M, Schneider S,
et al: Cell-free tumor DNA, CA125 and HE4 for the objective
assessment of tumor burden in patients with advanced high-grade
serous ovarian cancer. PLoS One. 17:e02627702022. View Article : Google Scholar : PubMed/NCBI
|
